Retrospective analysis compares outcomes of combining CDK4 6 inhibitors with endocrine therapy in metastatic patients, suggesting improved therapy options.
Endocrine therapy provides the cornerstone for treating estrogen receptor positive breast cancer, but certain tumors have intrinsic resistance, and developed resistance to hormone treatment is unavoidable in metastatic illness.
No takes yet. Share an insight, caveat, or question.
Sharehan Hassan Soliman (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: